 | • レポートコード：MRC2203A059 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の気管支拡張薬市場規模が、年平均4.7％成長すると予測しています。本市場調査レポートでは、気管支拡張薬の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤種類別（ベータアドレナリン作動性気管支拡張薬、キサンチン誘導体、抗コリン作用性気管支拡張薬）分析、投与経路別（口腔、注射、経鼻）分析、疾患別（喘息、慢性閉塞性肺疾患、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の気管支拡張薬市場規模：薬剤種類別（ベータアドレナリン作動性気管支拡張薬、キサンチン誘導体、抗コリン作用性気管支拡張薬） ・世界の気管支拡張薬市場規模：投与経路別（口腔、注射、経鼻） ・世界の気管支拡張薬市場規模：疾患別（喘息、慢性閉塞性肺疾患、その他） ・世界の気管支拡張薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AstraZeneca、Boehringer Ingelheim International GmbH、Cipla Inc.、…） ・市場機会・将来傾向 |
The bronchodilators market studied is expected to grow with an estimated CAGR of 4.7%, over the forecast period.
Substantial increase in the number of patients with respiratory disorders on an account of COVID-19 are projected to trigger the demand for bronchodilators across the globe. Several research studies suggest that the use of bronchodilator medications in treating COVID-19 patients can facilitate normal breathing and functional improvements. These medications are mainly useful in confirmed or suspected COVID-19 cases with reactive airway diseases. A June 2021 study published in Respiratory Medicine Journal, aimed at confirming the level of bronchodilator reversibility in SARS‑CoV‑2 patients undertaking multidisciplinary pulmonary rehabilitation after the acute phase. The study concluded that the use of bronchodilators should be considered in post-COVID-19 patients as it can encourage functional improvements in the lungs for normal breathing. However, some research studies contrast the usefulness of bronchodilators and conclude that no significant changes are observed in affected patients with minimal improvement in clinical outcomes for reducing the risk of mortality. For instance, recently, in 2021, a retrospective cohort study was carried to evaluate the association between the length of COVID-19 pneumonia patient stay in the hospitals and the use of inhaled bronchodilators in Spain. The results concluded from the study did not specify any notable health improvements among patients. As a result, the bronchodilators market is anticipated to be moderately impacted by the pandemic.
The studied market growth can be attributed to a variety of factors, such as the rising prevalence of respiratory diseases globally coupled with increased levels of air pollution, the surge in the number of smokers, and propelling incidence of infectious diseases among the elderly population significantly contributing toward the risk of developing lung disorders, and are collectively driving the market growth.
One of the key parameters responsible for the growth of the bronchodilators market is the gradual decrease in functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Additionally, a rising number of product launches and approvals are expected to have a positive impact on the demand for bronchodilators within the patient population. For instance, in July 2020, EVA Pharma launched ‘Inhalex’, the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half. On the contrary, possible side effects such as tremors, coughs, increased heart rate, and nervousness are likely to obstruct the market growth over the forecast period.
Key Market Trends
Asthma Segment is Expected to Register a Substantial Growth in the Bronchodilators Market
Based on indication, the asthma segment is estimated to garner significant growth throughout the forecast period. This is majorly attributed to the rising prevalence of asthma worldwide. For instance, as per World Health Organization (WHO) data, asthma affected around 262 million people in 2019 and triggered 461,000 deaths worldwide. Asthma is a breathing disorder caused due to narrowing of airway passages within the lungs. The narrowing may occur due to numerous reasons such as muscle spasms, excess production of mucus, or swelling in the airway. Amidst an asthma attack, the muscles in the airway begin to tighten, leading to narrowing of airways. Moreover, the lining of these passages tends to swell and results in the overproduction of mucus. This causes difficulty in breathing. Bronchodilators relieve these symptoms of asthma by opening the airways and counteract the effects of an attack. In addition, the surge in product approval and launches for treating asthma is further estimated to supplement the segment growth. For instance, in May 2019, Sanofi received a European Commission approval for its ‘Dupixent’ used in treating patients with severe asthma. Furthermore, United States Food and Drug Administration (USFDA) accepted ‘Dupixent’ for review in March 2021. Thus, the increasing number of pipeline products along with an upsurge in asthma-affected population and ease of availability of bronchodilator medications are expected to propel the growth of the bronchodilators market in the years to come.
North America is Expected to Hold a Major Share of the Market throughout the Forecast Period
Within North America, the United States has held the major share of the market and is expected to dominate over the forecast period. Chronic Obstructive Pulmonary Disease (COPD) affects millions of Americans each year and is the third foremost cause of disease-associated death in the United States. For instance, according to the data published by American Lung Association, in 2018, approximately 16.4 million adults in the United States reported a diagnosis of any type of COPD (emphysema, chronic bronchitis, or COPD). Likewise, asthma continues to be a serious public concern within the country. The United States Environmental Protection Agency and the National Health Interview Surveys (NHIS), in April 2021, estimated that almost 25.1 million people, comprising 5.1 million children, have asthma in the country. The same source also stated that, in 2019, over 10.3 million people with asthma, with nearly 2.3 million children, report having had one or more asthma attacks. Since bronchodilators are usually recommended as the first‐line of treatment for respiratory-related disorders, the North American region is anticipated to be the major revenue contributor throughout the analysis period. In addition, an upsurge in the number of smokers in the region along with a tremendous increase in environmental pollution are some of the other factors propelling the market growth for bronchodilators. Likewise, continuous R&D efforts of the regional market players for developing an efficacious treatment for patients with respiratory disorders is projected to impel the market growth. For instance, Regeneron Pharmaceuticals, Inc., an American biotechnology company collaborated with Sanofi for studying pediatric asthma. The drug candidate is currently in its Phase III clinical study and is estimated to be completed by September 2021.
Thus, these aformentioned factors collectively are responsible for driving the growth of bronchodilators market in North America.
Competitive Landscape
The bronchodilators market is highly competitive with several key players across the globe. In terms of market share, various major players currently dominate the market. With the rising patient awareness levels and high prevalence of respiratory diseases, many regional players are expected to be part of the bronchodilators market over the forecast period. Some of the major players of the market are Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Cipla Inc., and AstraZeneca among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Surge in Patient Population with Respiratory Disorders
4.2.2 Significant Rise in Environmental Pollution
4.2.3 Increasing Number of Smokers
4.3 Market Restraints
4.3.1 Side Effects of Bronchodilators
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Beta-Adrenergic Bronchodilators
5.1.2 Xanthine Derivatives
5.1.3 Anticholinergic Bronchodilators
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable
5.2.3 Nasal
5.3 By Indication
5.3.1 Asthma
5.3.2 Chronic Obstructive Pulmonary Disease
5.3.3 Other Indications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Cipla Inc.
6.1.4 GlaxoSmithKline plc
6.1.5 Harman Finochem Ltd
6.1.6 Innoviva
6.1.7 Novartis AG
6.1.8 Sanofi
6.1.9 Sunovion Pharmaceuticals
6.1.10 Teva Pharmaceutical Industries Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS